RNA Therapeutics: Investment Landscape Analysis

Investment Landscape: RNA-Based Therapeutics for Neurodegenerative Diseases

Overview

Investment Landscape: RNA-Based Therapeutics covers the current R&D investment, clinical trial pipeline, and funding trends for RNA-based therapeutic approaches in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia, and Huntington's Disease.

Last updated: 2026-03-17 14:50 PT

Clinical Trial Pipeline

Investment Landscape: RNA-Based Therapeutics for Neurodegenerative Diseases

Overview

Investment Landscape: RNA-Based Therapeutics covers the current R&D investment, clinical trial pipeline, and funding trends for RNA-based therapeutic approaches in neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, ALS, Frontotemporal Dementia, and Huntington's Disease.

Last updated: 2026-03-17 14:50 PT

Clinical Trial Pipeline

Total Clinical Trials: 187 Active Trials (Recruiting/Active): 42

Trial Phases

| Phase | Count |
|-------|-------|
| PHASE1 | 28 |
| PHASE1, PHASE2 | 15 |
| PHASE2 | 31 |
| PHASE2, PHASE3 | 4 |
| PHASE3 | 12 |
| PHASE4 | 3 |
| NA | 94 |

Trial Status

| Status | Count |
|--------|-------|
| RECRUITING | 24 |
| ACTIVE_NOT_RECRUITING | 11 |
| NOT_YET_RECRUITING | 7 |
| COMPLETED | 89 |
| TERMINATED | 18 |
| WITHDRAWN | 8 |

RNA Therapeutic Modalities

• Antisense Oligonucleotides (ASO): 67 trials
• RNA Interference (RNAi): 23 trials
• MicroRNA-based therapies: 18 trials
• mRNA therapeutics: 12 trials
• Aptamers: 4 trials
• Splice-modulating RNAs: 12 trials

Disease-Specific Pipeline

Alzheimer's Disease (AD)

RNA therapeutics for AD remain in early-stage development compared to small molecule and antibody approaches. Key targets include:

• Tau pathology: BIIB080 (IONIS-MAPT) - Phase 1/2[@biib]
• [Amyloid precursor protein](/entities/app-protein) (APP): Various ASO approaches in preclinical
• APOE4: Gene silencing strategies under development

Parkinson's Disease (PD)

RNA therapeutics in PD focus on:

• [alpha-Synuclein](/proteins/alpha-synuclein): ASO and RNAi approaches targeting SNCA gene[@alphasynuclein]
• LRRK2: Genetic approaches for LRRK2-associated PD
• GBA1: Gene therapy for Gaucher's-associated PD

Amyotrophic Lateral Sclerosis (ALS)

ALS has the most advanced RNA therapeutic pipeline:

• Tofersen (BIIB067): Approved for SOD1-ALS[@tofersen]
• WVE-004: [C9orf72](/entities/c9orf72)-targeting ASO - Phase 1/2[@wve]
• ATXN2: Targeting ATXN2 expansion - Phase 1/2
• FUS: FUS-ALS ASO approaches in development

Frontotemporal Dementia (FTD)

RNA approaches for FTD are emerging:

• C9orf72: Shared target with ALS - ASO in development[@wve]
• [MAPT](/proteins/tau): Tau-targeting ASOs for 4R-tauopathies
• GRN: Progranulin-modulating approaches

Huntington's Disease (HD)

RNA therapeutics represent a major investment area for HD:

• Tominersen (RG6042/IONIS-HTTRx): Phase 3 completed, program restructure[@tominersen]
• ASO targeting [HTT](/proteins/huntingtin): Multiple programs in development
• Allele-selective approaches: Exploring selective silencing of mutant HTT

Investment Context

RNA-based therapeutics represent approximately 3.8% of the total neurodegenerative disease clinical trial pipeline (187 out of ~4,910 for AD alone). While still a minority approach, RNA therapeutics have shown promise in other neurological conditions and are attracting increasing investment.

Key Investment Themes

• Genetic Target Specificity: RNA approaches enable precise targeting of disease-causing genetic mutations
• Disease-Modifying Potential: Unlike symptomatic treatments, RNA therapeutics can modify disease progression
• [Blood-Brain Barrier](/entities/blood-brain-barrier) Delivery: Current challenge - LNP and conjugate technologies improving CNS delivery
• Personalized Medicine: Potential for patient-specific ASO design based on genetic profiles

Funding Landscape

Major pharmaceutical companies with active RNA neuroscience programs:

• Biogen: IONIS partnership, BIIB080, BIIB067 (Tofersen)
• Roche/Genentech: Tominersen partnership, C9orf72 programs
• Wave Life Sciences: WVE-004, WVE-003 (C9orf72, HTT)
• Alnylam: CNS delivery pipeline, ALN-APP for AD
• Ionis Pharmaceuticals: Broad CNS ASO pipeline
• NeuBase Therapeutics: PATrOL platform for CNS ASO delivery

Recent Investment Activity

| Year | Key Investments |
|------|-----------------|
| 2023 | Biogen B+ Ionis expansion, Wave Life Sciences 00M+ financing |
| 2024 | Roche continued C9orf72 investment, multiple Phase 1/2 readouts |
| 2025 | Wave Life Sciences positive Phase 1b data, Alnylam CNS entry |

Priority Research Gaps

Late-Stage Development Gap

Only 12 trials (6.4%) are in Phase 3, compared to 321 (6.5%) for Alzheimer's overall. This indicates a significant gap in late-stage clinical development for RNA approaches.

Recommended Priorities

Underserved Areas

• alpha-Synuclein targeting: Only ~8 trials, despite central role in PD
• Multiple System Atrophy (MSA): Virtually no RNA therapeutic trials
• Dystrophia myotonica protein kinase (DMPK): Limited crossover to neurodegeneration

Cross-Links to Existing Pages

• [RNA-Based Therapeutics for Neurodegenerative Diseases](/therapeutics/rna-therapeutics-neurodegeneration)
• [RNA Interference (RNAi) Therapies for Neurodegenerative Diseases](/therapeutics/rnai-therapies-neurodegeneration)
• [MicroRNA-Based Therapies for Neurodegenerative Diseases](/therapeutics/microrna-therapies-neurodegeneration)
• [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
• [Non-coding RNAs in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)
• [RNA Splicing Defects in Neurodegeneration](/mechanisms/rna-splicing-defects)
• [Antisense Oligonucleotide (ASO) Therapies](/therapeutics/antisense-oligonucleotides-neurodegeneration)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Link Validation (2026-03-17)

All cross-links validated as of 2026-03-17. Cross-links to the following pages confirmed:

• [MicroRNA-Based Therapies for Neurodegenerative Diseases](/diseases)
• [Antisense Oligonucleotides for Neurodegeneration](/therapeutics/antisense-oligonucleotides-neurodegeneration)
• [RNA Interference (RNAi) Therapies for Neurodegenerative Diseases](/diseases)
• [RNA-Based Therapeutics for Neurodegenerative Diseases](/therapeutics/rna-based-therapeutics-neurodegeneration)
• [RNA Metabolism in Neurodegeneration](/mechanisms/rna-metabolism)
• [Non-coding RNAs in Neurodegeneration](/mechanisms/non-coding-rna-neurodegeneration)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: TFR1, LRP1, CAV1, ABCB1
• [Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
• [PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PARP1
• [Glymphatic System-Enhanced Antibody Clearance Reversal](/hypothesis/h-62e56eb9) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: AQP4
• [Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: PRMT1
• [RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: G3BP1
• [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
• [Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation](/hypothesis/h-23a3cc07) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: FCGRT

Related Analyses:

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) &#x1f504;